TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial

TriSalus Life Sciences Inc. (NASDAQ:TLSI) is one of the best fast growing penny stocks to buy right now. On May 4, TriSalus Life Sciences initiated patient enrollment for the PREDICTT clinical trial, a prospective study evaluating its proprietary Pressure-Enabled Drug Delivery/PEDD technology in patients with primary or metastatic liver tumors. Conducted at The University of Texas MD Anderson Cancer Center, the study uses the TriNav Infusion System to deliver Y90 radioembolization therapy.

The goal is to determine if this pressure-enabled approach can enhance tumor targeting and improve the distribution of radiation doses compared to traditional methods. The investigator-led trial will enroll approximately 20 adult patients with unresectable tumors to analyze how the TriNav system affects tumor-to-normal liver enhancement ratios. Researchers will use CT and SPECT/CT imaging to correlate these measurements with actual microsphere distribution and overall treatment outcomes.

TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial

This focus on precision delivery aims to maximize the therapeutic dose to the tumor while minimizing exposure to healthy surrounding liver tissue. The collaboration with MD Anderson represents an effort to generate clinical evidence that could redefine the standard of care for liver-directed therapies. By assessing the safety and efficacy of the TriNav system in conjunction with Y90, TriSalus seeks to address the long-standing challenge of optimizing drug delivery in solid tumors.

TriSalus Life Sciences Inc. (NASDAQ:TLSI) develops drug delivery technology platforms and immuno-oncology therapeutics aimed at improving outcomes for patients with difficult-to-treat liver and pancreatic cancers in the US.

While we acknowledge the risk and potential of TLSI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TLSI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.